InVivoSIM anti-human CD19 (Loncastuximab Biosimilar)

Catalog #SIM0075
Clone:
Loncastuximab

$235.00 - $8,140.00

$235.00 - $8.00

Choose an Option...
  • 100 mg - $8,140.00
  • 50 mg - $4,574.00
  • 25 mg - $3,182.00
  • 5 mg - $911.00
  • 1 mg - $235.00
  • Custom Amount (Quotes Only)
In stock
Only %1 left

Product Details

This non-therapeutic biosimilar antibody uses the same variable regions as the therapeutic antibody, loncastuximab, making it ideal for research use. Loncastuximab is a humanized IgG1, k monoclonal antibody that reacts with the human B-cell marker CD19, a membrane glycoprotein of the immunoglobulin superfamily that is expressed at the various stages of B-cell development and is detectable in most B-cell malignancies. CD19 is an ideal target for antibody-drug conjugates (ADCs) and other therapies because it plays a key role in lymphocyte biology, is uniquely expressed on B cells, and is rapidly internalized without shedding into the bloodstream. These properties make it especially valuable in research on B cells and relapsed or refractory diffuse large B-cell lymphoma (DLBCL), the most common form of non-Hodgkin lymphoma. Loncastuximab tesirine is a human CD19-directed ADC, wherein the antibody is conjugated through a cathepsin-cleavable linker to SG3199, a potent pyrrolobenzodiazepine dimer alkylating cytotoxin. Upon binding to CD19 on the cell membrane, the ADC is internalized and transported to lysosomes, where it is cleaved to release the drug inside the cells, ultimately inducing apoptotic cell death through the crosslinking of DNA. In vitro experiments using loncastuximab tesirine in multiple lymphoma cell lines demonstrated this ADC’s strong cytotoxic activity that correlated with the level of CD19 expression. The in vivo treatment of loncastuximab tesirine is also reported to show dose-dependent antitumor activity in human CD19-expressing Burkitt lymphoma-derived Ramos models (subcutaneous as well as disseminated xenograft models involving Ramos and NALM-6 cells).

Specifications

Isotype Human IgG1, Īŗ
Recommended Isotype Control(s) RecombiMAb human IgG1 isotype control, anti-hen egg lysozyme
Recommended Dilution Buffer InVivoPure pH 6.0T Dilution Buffer
Immunogen Human CD19
Reported Applications Antibody-drug conjugate synthesis
In vivo functional assays
in vitro functional assays
Flow cytometry
ELISA
Formulation PBS, pH 6.0
Contains no stabilizers or preservatives
Endotoxin <0.5EU/mg (<0.0005EU/μg)
Determined by LAL gel clotting assay
Aggregation <5%
Determined by SEC
Purity >95%
Determined by SDS-PAGE
Sterility 0.2 µm filtration
Production Purified from cell culture supernatant in an animal-free facility
Purification Protein A
Molecular Weight 150 kDa
Murine Pathogen Tests Ectromelia/Mousepox Virus: Negative
Hantavirus: Negative
K Virus: Negative
Lactate Dehydrogenase-Elevating Virus: Negative
Lymphocytic Choriomeningitis virus: Negative
Mouse Adenovirus: Negative
Mouse Cytomegalovirus: Negative
Mouse Hepatitis Virus: Negative
Mouse Minute Virus: Negative
Mouse Norovirus: Negative
Mouse Parvovirus: Negative
Mouse Rotavirus: Negative
Mycoplasma Pulmonis: Negative
Pneumonia Virus of Mice: Negative
Polyoma Virus: Negative
Reovirus Screen: Negative
Sendai Virus: Negative
Theiler’s Murine Encephalomyelitis: Negative
Storage The antibody solution should be stored at the stock concentration at 4°C. Do not freeze.